ONG DIKO

Email

contact@ongdiko.org

Phone

T: +22796161619

Web

https://ongdiko.org/

Address

Rue kk 138, Niamey, Niger 8000
About ONG DIKO

ONG DIKO is a Nigerien African non-governmental development and humanitarian organisation with a universal vocation and based on ethical values ​​that guide its work. It was created on October 22, 2006 by young progressive students and rights activists under the name “Association pour le Secours aux Populations Vulnérables (ASPV)”. In 2009, this association evolved into an NGO by  ministerial decree with the name DIKO, which means “SUPPORT” in the Djerma language.

Its mission is to support vulnerable populations, particularly women, children, and people with special needs, by promoting social justice, combating inequality, and respecting human rights. They operate using an approach based primarily on human rights.

ONG DIKO works to prevent water-related diseases, hygiene, and sanitation, including hepatitis A and E caused by the consumption of water or food contaminated by faecal matter. Their interventions focus on access to safe drinking water and adequate sanitation through targeted awareness-raising, advocacy, capacity building, the provision of hygiene kits and infrastructure, etc., for the benefit of vulnerable populations. Their commitment to the fight against hepatitis goes far beyond their daily advocacy efforts, raising awareness among authorities, training healthcare personnel, and increasing access to health centres. With 10 years of experience in the field, they have developed in-depth expertise and a nuanced understanding of the multiple facets of this public health issue. Their holistic approach translates into significant involvement in [mention other specific areas of expertise here, for example:

  • Prevention and early detection: They have implemented targeted community awareness campaigns, using innovative approaches to inform at-risk populations about the modes of transmission, the importance of screening, and the benefits of early treatment.
  • Psychosocial support for patients and their families: Aware of the emotional and social impact of hepatitis, they offer psychosocial support, support groups, and resources to help patients cope with the disease and improve their quality of life.
  • Promoting favourable public policies: Their expertise allows us to actively contribute to the development and implementation of public policies aimed at strengthening prevention, screening, treatment, and access to care for people living with hepatitis.
  • Research and data collection: They actively participate in the collection of epidemiological data and studies aimed at better understanding the prevalence of hepatitis in our specific context, as well as evaluating the effectiveness of implemented interventions.
  • Advocacy for access to affordable treatment: They actively engage in advocacy to ensure equitable and affordable access to antiviral treatments and other necessary care for people with hepatitis.
  • Capacity building for local stakeholders: Beyond training healthcare personnel, they work to build the capacity of community organisations and local stakeholders so they can play an active role in the fight against hepatitis within their communities.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close